Bertram Wiedenmann

List of Publications by Year
in descending order

272 papers	25,864 citations	5876 81 h-index	7136 153 g-index
278 all docs	278 docs citations	278 times ranked	25938 citing authors

#	Article	IF	Citations
1	Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 2011, 364, 501-513.	13.9	2,216
2	Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell, 1985, 41, 1017-1028.	13.5	1,394
3	A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nature Medicine, 2013, 19, 619-625.	15.2	831
4	ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary. Neuroendocrinology, 2012, 95, 157-176.	1.2	774
5	Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial. Journal of Clinical Oncology, 2010, 28, 69-76.	0.8	628
6	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Annals of Oncology, 2015, 26, 1604-1620.	0.6	514
7	Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nature Biotechnology, 2001, 19, 327-331.	9.4	495
8	Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumorsâ€"The International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology, 2003, 21, 2689-2696.	0.8	476
9	Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer, 2008, 113, 256-265.	2.0	394
10	Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nature Genetics, 2008, 40, 78-82.	9.4	369
11	Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. Journal of Gastroenterology, 2010, 45, 234-243.	2.3	354
12	Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology, 2004, 40, 1421-1425.	3.6	341
13	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology, 2017, 105, 212-244.	1.2	325
14	Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer, 2008, 15, 1083-1097.	1.6	324
15	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a Standardized Approach to the Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors and Their Prognostic Stratification. Neuroendocrinology, 2009, 90, 162-166.	1.2	313
16	Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology, 2010, 51, 73-80.	3.6	303
17	Synaptophysin and chromogranins/secretogranins widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Vigiliae Christianae, 1989, 58, 95-121.	0.1	294
18	Effects of Interferon Alpha on Vascular Endothelial Growth Factor Gene Transcription and Tumor Angiogenesis. Journal of the National Cancer Institute, 2003, 95, 437-448.	3.0	293

#	Article	IF	Citations
19	Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression. Cancer Research, 2008, 68, 9788-9798.	0.4	287
20	Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology, 2006, 44, 318-325.	3.6	278
21	Pancreatic carcinoma. Lancet, The, 1997, 349, 485-489.	6.3	255
22	Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nature Genetics, 2013, 45, 1216-1220.	9.4	255
23	Neuroendocrine tumors of midgut and hindgut origin: Tumorâ€nodeâ€metastasis classification determines clinical outcome. Cancer, 2011, 117, 3332-3341.	2.0	254
24	Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma. Neuroendocrinology, 2006, 84, 183-188.	1.2	248
25	Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology, 2003, 37, 600-609.	3.6	247
26	Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology, 2003, 125, 891-905.	0.6	230
27	Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors â€“ Well-Differentiated Jejunal-Ileal Tumor/Carcinoma. Neuroendocrinology, 2008, 87, 8-19.	1.2	222
28	A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nature Genetics, 2006, 38, 668-673.	9.4	220
29	Omega-3 fatty acids and their lipid mediators: Towards an understanding of resolvin and protectin formation. Prostaglandins and Other Lipid Mediators, 2012, 97, 73-82.	1.0	218
30	The majority of intestinal IgA+ and IgG+ plasmablasts in the human gut are antigen-specific. Journal of Clinical Investigation, 2011, 121, 1946-1955.	3.9	214
31	Narrow-Band Versus White-Light High Definition Television Endoscopic Imaging for Screening Colonoscopy: A Prospective Randomized Trial. Gastroenterology, 2009, 136, 410-416.e1.	0.6	194
32	Human Galectin-2: Novel Inducer of T Cell Apoptosis with Distinct Profile of Caspase Activation. Journal of Immunology, 2004, 173, 3825-3837.	0.4	193
33	Factors determining the quality of screening colonoscopy: a prospective study on adenoma detection rates, from 12â€“134 examinations (Berlin colonoscopy project 3, BECOP-3). Gut, 2013, 62, 236-241.	6.1	192
34	Synaptophysin: A novel marker for neurons, certain neuroendocrine cells, and their neoplasms. Human Pathology, 1986, 17, 979-983.	1.1	187
35	Magnetic resonance cholangiopancreatography-guided unilateral endoscopic stent placement for Klatskin tumors. Gastrointestinal Endoscopy, 2001, 53, 40-46.	0.5	181
36	Tacrolimus Is Safe and Effective in Patients with Severe Steroid-Refractory or Steroid-Dependent Inflammatory Bowel Disease-A Long-Term Follow-Up. American Journal of Gastroenterology, 2006, 101, 1048-1056.	0.2	170

#	Article	IF	Citations
37	Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocrine-Related Cancer, 2012, 19, 657-666.	1.6	169
38	Oxidative Stress Regulates Vascular Endothelial Growth Factor-A Gene Transcription through Sp1- and Sp3-dependent Activation of Two Proximal GC-rich Promoter Elements. Journal of Biological Chemistry, 2003, 278, 8190-8198.	1.6	168
39	Neuroendocrine neoplasms of the gut and pancreas: new insights. Nature Reviews Endocrinology, 2012, 8, 54-64.	4.3	168
40	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nature Genetics, 2018, 50, 979-989.	9.4	168
41	Desacyl ghrelin inhibits the orexigenic effect of peripherally injected ghrelin in rats. Peptides, 2008, 29, 2159-2168.	1.2	159
42	Stromal R-spondin orchestrates gastric epithelial stem cells and gland homeostasis. Nature, 2017, 548, 451-455.	13.7	159
43	Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocrine-Related Cancer, 2008, 15, 229-241.	1.6	158
44	Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterology, 2014, 14, 183.	0.8	156
45	Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide. Neuroendocrinology, 2004, 80, 244-251.	1.2	152
46	Galectin-1 Interacts with the Î±5Î²1 Fibronectin Receptor to Restrict Carcinoma Cell Growth via Induction of p21 and p27. Journal of Biological Chemistry, 2005, 280, 37266-37277.	1.6	148
47	Prospective Evaluation of Pancreatic Tumors: Accuracy of MR Imaging with MR Cholangiopancreatography and MR Angiography. Radiology, 2002, 224, 34-41.	3.6	147
48	A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. Cancer Discovery, 2015, 5, 1296-1313.	7.7	145
49	Tumor suppressor p16INK4aâ€ƒâ€™â€ƒmodulator of glycomic profile and galectin-1 expression to increase susceptibility to carbohydrate-dependent induction of anoikis in pancreatic carcinoma cells. FEBS Journal, 2007, 274, 3233-3256.	2.2	141
50	Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Research, 2003, 63, 1083-92.	0.4	140
51	Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World Journal of Gastroenterology, 2010, 16, 3168.	1.4	128
52	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. Neuroendocrinology, 2017, 105, 201-211.	1.2	127
53	Survival and Clinical Outcome of Patients with Neuroendocrine Tumors of the Gastroenteropancreatic Tract in a German Referral Center. Annals of the New York Academy of Sciences, 2004, 1014, 222-233.	1.8	123
54	Escherichia coli Nissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling. Infection and Immunity, 2005, 73, 1452-1465.	1.0	123

#	Article	IF	Citations
55	EUS-guided FNA of solid pancreatic masses: high yield of 2 passes with combined histologic-cytologic analysis. Gastrointestinal Endoscopy, 2009, 70, 60-69.	0.5	122
56	An outbreak of carbapenem-resistant OXA-48 â€“ producing Klebsiella pneumonia associated to duodenoscopy. Antimicrobial Resistance and Infection Control, 2015, 4, 8.	1.5	121
57	Impact of Multiphase ⁶⁸Ga-DOTATOC-PET/CT on Therapy Management in Patients with Neuroendocrine Tumors. Neuroendocrinology, 2010, 91, 101-109.	1.2	118
58	Synthesis, Characterization, and Biological Properties of Cyanine-Labeled Somatostatin Analogues as Receptor-Targeted Fluorescent Probes. Bioconjugate Chemistry, 2001, 12, 44-50.	1.8	116
59	Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology, 2002, 123, 1889-1903.	0.6	115
60	Hypoxia-Inducible Factor 1Î± Determines Gastric Cancer Chemosensitivity via Modulation of p53 and NF-ÎºB. PLoS ONE, 2010, 5, e12038.	1.1	110
61	Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. International Journal of Molecular Sciences, 2019, 20, 3049.	1.8	110
62	Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1386-92.	3.3	109
63	A Novel Function for the Tumor Suppressor p16INK4a. Journal of Cell Biology, 2000, 150, 1467-1478.	2.3	108
64	Characterization of Somatostatin Receptor Subtype-Specific Regulation of Insulin and Glucagon Secretion: An in Vitro Study on Isolated Human Pancreatic Islets. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 673-680.	1.8	104
65	Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-Î± on tight junction proteins and signaling pathways in intestinal epithelial cells. American Journal of Physiology - Renal Physiology, 2013, 304, G970-G979.	1.6	103
66	Galectin-4 Controls Intestinal Inflammation by Selective Regulation of Peripheral and Mucosal T Cell Apoptosis and Cell Cycle. PLoS ONE, 2008, 3, e2629.	1.1	100
67	Telotristat Etiprate for Carcinoid Syndrome: A Single-Arm, Multicenter Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1511-1519.	1.8	99
68	Autoregulation of Th1-mediated inflammation by twist1 . Journal of Experimental Medicine, 2008, 205, 1889-1901.	4.2	96
69	Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget, 2015, 6, 2549-2561.	0.8	96
70	The German NET-Registry: An Audit on the Diagnosis and Therapy of Neuroendocrine Tumors. Neuroendocrinology, 2009, 90, 349-363.	1.2	95
71	Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. European Journal of Cancer, 2015, 51, 1253-1262.	1.3	95
72	Axon Guidance Factor SLIT2 Inhibits Neural Invasion and Metastasis in Pancreatic Cancer. Cancer Research, 2014, 74, 1529-1540.	0.4	92

#	Article	IF	Citations
73	Intraperitoneal injection of ghrelin induces Fos expression in the paraventricular nucleus of the hypothalamus in rats. Brain Research, 2003, 991, 26-33.	1.1	91
74	Identification of gastroenteropancreatic neuroendocrine cells in normal and neoplastic human tissue with antibodies against synaptophysin, chromogranin A, secretogranin I (chromogranin B), and secretogranin II. Gastroenterology, 1988, 95, 1364-1374.	0.6	90
75	A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. Journal of Hepatology, 2007, 47, 203-211.	1.8	90
76	mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer, 2011, 18, 181-192.	1.6	90
77	⁶⁸Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol. Journal of Nuclear Medicine, 2011, 52, 697-704.	2.8	89
78	Helicobacter pyloristimulates host cyclooxygenase-2 gene transcription: critical importance of MEK/ERK-dependent activation of USF1/-2 and CREB transcription factors. Cellular Microbiology, 2003, 5, 821-834.	1.1	87
79	Hypoxia-Inducible Factor 1Î± Mediates Anoikis Resistance via Suppression of Î±5 Integrin. Cancer Research, 2008, 68, 10113-10120.	0.4	87
80	Malnutrition Predicts Clinical Outcome in Patients with Neuroendocrine Neoplasia. Neuroendocrinology, 2017, 104, 11-25.	1.2	86
81	A motor-driven single-use colonoscope controlled with a hand-held device: a feasibility study in volunteers. Gastrointestinal Endoscopy, 2008, 67, 1139-1146.	0.5	84
82	Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice. Journal of Molecular Medicine, 2008, 86, 1395-1406.	1.7	83
83	Tumor-Associated Angiogenesis and Lymphangiogenesis Correlate With Progression of Intrahepatic Cholangiocarcinoma. American Journal of Gastroenterology, 2010, 105, 1123-1132.	0.2	83
84	Interferon-Î± delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology, 2001, 33, 346-356.	3.6	80
85	The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer. Clinical Cancer Research, 2008, 14, 4951-4960.	3.2	80
86	Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches. Clinical Cancer Research, 2013, 19, 2842-2849.	3.2	80
87	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. Neuroendocrinology, 2018, 107, 375-386.	1.2	78
88	A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. The Journal of Supportive Oncology, 2008, 6, 18-25.	2.3	77
89	Angiopoietin-2 Promotes Disease Progression of Neuroendocrine Tumors. Clinical Cancer Research, 2010, 16, 420-429.	3.2	76
90	ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update. Neuroendocrinology, 2012, 95, 71-73.	1.2	75

#	Article	IF	Citations
91	Fractionation of synaptophysin-containing vesicles from rat brain and cultured PC12 pheochromocytoma cells. FEBS Letters, 1988, 240, 71-77.	1.3	73
92	CCK inhibits the orexigenic effect of peripheral ghrelin. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2005, 288, R751-R758.	0.9	69
93	Molecular mechanism of interferon alfaâ€"Mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology, 2000, 118, 735-748.	0.6	68
94	Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1. American Journal of Physiology - Renal Physiology, 2014, 306, G218-G228.	1.6	67
95	Helicobacter pylori Activates the Histidine Decarboxylase Promoter through a Mitogen-activated Protein Kinase Pathway Independent of Pathogenicity Island-encoded Virulence Factors. Journal of Biological Chemistry, 2000, 275, 3629-3636.	1.6	66
96	Galectin-2 and -4, but not Galectin-1, promote intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. Inflammatory Bowel Diseases, 2008, 14, 1366-1372.	0.9	66
97	Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver International, 2011, 31, 1574-1588.	1.9	66
98	Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis. Hepatology, 2007, 46, 1155-1165.	3.6	65
99	ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine Tumors. Neuroendocrinology, 2010, 91, 341-350.	1.2	65
100	Retinoids: Effects on growth, differentiation, and nuclear receptor expression in human pancreatic carcinoma cell lines. Gastroenterology, 1995, 109, 1646-1660.	0.6	64
101	Sp1 and CREB Mediate Gastrin-dependent Regulation of Chromogranin A Promoter Activity in Gastric Carcinoma Cells. Journal of Biological Chemistry, 1998, 273, 34000-34007.	1.6	64
102	Angiopoietinâ€2 drives lymphatic metastasis of pancreatic cancer. FASEB Journal, 2011, 25, 3325-3335.	0.2	64
103	Mutations in the MEN I gene in sporadic neuroendocrine tumours of gastroenteropancreatic system. Lancet, The, 1997, 350, 1223.	6.3	63
104	Helicobacter pylori stimulates host vascular endothelial growth factorâ€A (vegfâ€A) gene expression via MEK/ERKâ€dependent activation of Sp1 and Sp3. FASEB Journal, 2004, 18, 218-220.	0.2	63
105	Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome â€" An International Consensus Statement. Neuroendocrinology, 2021, 111, 609-630.	1.2	63
106	Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. Hepatology, 2000, 32, 1386-1395.	3.6	61
107	Synaptophysin expressed in the bronchopulmonary tract: Neuroendocrine cells, neuroepithelial bodies, and neuroendocrine neoplasms. Differentiation, 1987, 34, 115-125.	1.0	60
108	Oxidative Stress Activates the Human Histidine Decarboxylase Promoter in AGS Gastric Cancer Cells. Journal of Biological Chemistry, 1998, 273, 23046-23054.	1.6	60

#	Article	IF	Citations
109	Novel insight in distribution of nesfatin-1 and phospho-mTOR in the arcuate nucleus of the hypothalamus of rats. Peptides, 2010, 31, 257-262.	1.2	60
110	Diagnostic and therapeutic single-operator cholangiopancreatoscopy with SpyGlassDSâ„¢: results of a multicenter retrospective cohort study. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 3981-3988.	1.3	60
111	Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. Journal of Hepatology, 2004, 41, 652-658.	1.8	56
112	VEGFâ€Ð promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma. International Journal of Cancer, 2008, 122, 2471-2481.	2.3	56
113	Angiopoietin-2 Serum Levels Are Elevated in Patients With Liver Cirrhosis and Hepatocellular Carcinoma. American Journal of Gastroenterology, 2007, 102, 2471-2481.	0.2	55
114	CCK-8S activates c-Fos in a dose-dependent manner in nesfatin-1 immunoreactive neurons in the paraventricular nucleus of the hypothalamus and in the nucleus of the solitary tract of the brainstem. Regulatory Peptides, 2009, 157, 84-91.	1.9	55
115	Galectins distinctively regulate central monocyte and macrophage function. Cellular Immunology, 2011, 271, 97-103.	1.4	54
116	Latest Generation, Wide-Angle, High-Definition Colonoscopes Increase Adenoma Detection Rate. Clinical Gastroenterology and Hepatology, 2012, 10, 155-159.	2.4	53
117	Increased T-Helper 2 Cytokines in Bile From Patients With IgG4-Related Cholangitis Disrupt the Tight Junctionâ€“Associated Biliary Epithelial Cell Barrier. Gastroenterology, 2013, 144, 1116-1128.	0.6	53
118	R-spondin-3 induces secretory, antimicrobial Lgr5+ cells in the stomach. Nature Cell Biology, 2019, 21, 812-823.	4.6	53
119	Interaction of Early Growth Response Protein 1 (Egr-1), Specificity Protein 1 (Sp1), and Cyclic Adenosine 3â€²5â€²-Monophosphate Response Element Binding Protein (CREB) at a Proximal Response Element Is Critical for Gastrin-Dependent Activation of the Chromogranin A Promoter. Molecular Endocrinology, 2002, 16, 2802-2818.	3.7	52
120	ClC-3 expression enhances etoposide resistance by increasing acidification of the late endocytic compartment. Molecular Cancer Therapeutics, 2007, 6, 979-986.	1.9	52
121	CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway. Cytokine, 2004, 29, 42-8.	1.4	51
122	Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. European Journal of Gastroenterology and Hepatology, 2007, 19, 947-951.	0.8	51
123	Orexin-A Inhibits Glucagon Secretion and Gene Expression through a Foxo1-Dependent Pathway. Endocrinology, 2008, 149, 1618-1626.	1.4	49
124	Peripheral injection of ghrelin induces Fos expression in the dorsomedial hypothalamic nucleus in rats. Brain Research, 2008, 1204, 77-86.	1.1	48
125	Is desacyl ghrelin a modulator of food intake?. Peptides, 2009, 30, 991-994.	1.2	48
126	Lipoxins and resolvins in inflammatory bowel disease. Inflammatory Bowel Diseases, 2007, 13, 797-799.	0.9	47

#	Article	IF	Citations
127	Microvessel density correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. Journal of Gastroenterology, 2008, 43, 959-966.	2.3	47
128	Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1684-1693.	3.3	46
129	Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection. Journal of Hepatology, 2007, 46, 372-380.	1.8	46
130	A complete substitutional analysis of VIP for better tumor imaging properties. Journal of Molecular Recognition, 2002, 15, 145-153.	1.1	45
131	Transient Receptor Potential Channel TRPM8 Agonists Stimulate Calcium Influx and Neurotensin Secretion in Neuroendocrine Tumor Cells. Neuroendocrinology, 2007, 85, 81-92.	1.2	45
132	Refractory Sprue Syndrome with Clonal Intraepithelial Lymphocytes Evolving into Overt Enteropathy-Type Intestinal T-Cell Lymphoma. Digestion, 2000, 62, 60-65.	1.2	44
133	Experience with teduglutide treatment for short bowel syndrome in clinical practice. Clinical Nutrition, 2019, 38, 1745-1755.	2.3	44
134	Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. Annals of Surgical Oncology, 2020, 27, 1348-1355.	0.7	44
135	Dynamics of GB Virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication. Hepatology, 1999, 29, 245-249.	3.6	43
136	The probiotic Escherichia coli strain Nissle 1917 induces Î³Î´ T cell apoptosis via caspase- and FasL-dependent pathways. International Immunology, 2008, 20, 829-840.	1.8	43
137	Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nature Reviews Endocrinology, 2020, 16, 590-607.	4.3	43
138	Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: Why Such Guidelines and How We Went about It. Neuroendocrinology, 2006, 84, 155-157.	1.2	43
139	Obestatin in human neuroendocrine tissues and tumours: expression and effect on tumour growth. Journal of Pathology, 2009, 218, 458-466.	2.1	42
140	The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. Digestive and Liver Disease, 2014, 46, 903-908.	0.4	42
141	Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. Oncologist, 2017, 22, 409-415.	1.9	42
142	Bâ€Raf/Rap1 signaling, but not câ€Rafâ€1/Ras, induces the histidine decarboxylase promoter in Helicobacter pylori infection. FASEB Journal, 2002, 16, 417-419.	0.2	41
143	Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cellsâ˜†. Gastroenterology, 2004, 126, 1828-1843.	0.6	41
144	Secretin receptors in the human liver: Expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma. Journal of Hepatology, 2006, 45, 825-835.	1.8	41

#	Article	IF	Citations
145	Tumor-Associated Lymphangiogenesis Correlates with Lymph Node Metastases and Prognosis in Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2008, 15, 791-799.	0.7	41
146	Peripheral obestatin has no effect on feeding behavior and brain Fos expression in rodents. Peptides, 2008, 29, 1018-1027.	1.2	41
147	Proteomic Analysis of the Inflamed Intestinal Mucosa Reveals Distinctive Immune Response Profiles in Crohnâ€™s Disease and Ulcerative Colitis. Journal of Immunology, 2007, 179, 295-304.	0.4	40
148	EndoClot Polysaccharide Hemostatic System in Nonvariceal Gastrointestinal Bleeding. Journal of Clinical Gastroenterology, 2016, 50, e95-e100.	1.1	40
149	Synaptophysin Identified in Metastases of Neuroendocrine Tumors by Immunocytochemistry and Immunoblotting. American Journal of Clinical Pathology, 1987, 88, 560-569.	0.4	39
150	Common biostructure of the colonic microbiota in neuroendocrine tumors and CrohnÊ¼s disease and the effect of therapy. Inflammatory Bowel Diseases, 2012, 18, 1663-1671.	0.9	38
151	Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma. Gastroenterology, 2002, 122, 500-511.	0.6	37
152	Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma. Histochemistry and Cell Biology, 2009, 132, 21-31.	0.8	36
153	Thermo-sensitive transient receptor potential vanilloid channel-1 regulates intracellular calcium and triggers chromogranin A secretion in pancreatic neuroendocrine BON-1 tumor cells. Cellular Signalling, 2012, 24, 233-246.	1.7	36
154	Endosonography of Neuroendocrine Tumors of the Stomach, Duodenum, and Pancreas. Annals of the New York Academy of Sciences, 1994, 733, 425-436.	1.8	35
155	Peripheral injection of CCK-8S induces Fos expression in the dorsomedial hypothalamic nucleus in rats. Brain Research, 2006, 1117, 109-117.	1.1	35
156	Data quality of the German Screening Colonoscopy Registry. Endoscopy, 2013, 45, 813-818.	1.0	35
157	Overexpression of pRB in Human Pancreatic Carcinoma Cells: Function in Chemotherapy-Induced Apoptosis. Journal of the National Cancer Institute, 2002, 94, 129-142.	3.0	34
158	Mesalamine promotes intestinal epithelial wound healingin vitrothrough a TGF-beta-independent mechanism. Scandinavian Journal of Gastroenterology, 2005, 40, 958-964.	0.6	34
159	Somatostatin Receptor Subtype-2-Deficient Mice with Diet-Induced Obesity Have Hyperglycemia, Nonfasting Hyperglucagonemia, and Decreased Hepatic Glycogen Deposition. Endocrinology, 2007, 148, 3887-3899.	1.4	34
160	Probiotic carbohydrates reduce intestinal permeability and inflammation in metabolic diseases. Gut, 2009, 58, 1044-1045.	6.1	34
161	Role of hypoxia-inducible transcription factor 1Î± for progression and chemosensitivity of murine hepatocellular carcinoma. Journal of Molecular Medicine, 2010, 88, 817-827.	1.7	34
162	From Targets to Treatments: A Review of Molecular Targets in Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2011, 94, 177-190.	1.2	34

#	Article	IF	Citations
163	A Duodenal Gastrinoma in a Patient with Diarrhea and Normal Serum Gastrin Concentrations. New England Journal of Medicine, 1995, 333, 634-637.	13.9	33
164	Gastric Perception Thresholds Are Low and Sensory Neuropeptide Levels High in Helicobacter pylori-Positive Functional Dyspepsia. Digestion, 2005, 71, 111-123.	1.2	33
165	The c.1-260C>T Promoter Variant of CD14 but Not the c.896A>G (p.D299G) Variant of Toll-Like Receptor 4 (TLR4) Genes Is Associated with Inflammatory Bowel Disease. Digestion, 2007, 76, 196-202.	1.2	33
166	Enteral and parenteral nutrition distinctively modulate intestinal permeability and T cell function in vitro. European Journal of Nutrition, 2009, 48, 12-21.	1.8	33
167	Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferonÎ² 1a. World Journal of Gastroenterology, 2007, 13, 3638.	1.4	33
168	Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. Hepatology, 2003, 38, 1592-1592.	3.6	32
169	Tumor-Associated Lymphangiogenesis Correlates with Prognosis after Resection of Human Hepatocellular Carcinoma. Annals of Surgical Oncology, 2009, 16, 1222-1230.	0.7	32
170	Downregulation of p21waf/cip-1 mediates apoptosis of human hepatocellular carcinoma cells in response to interferon-Î³. Experimental Cell Research, 2003, 282, 78-89.	1.2	31
171	PuraStat in gastrointestinal bleeding: results of a prospective multicentre observational pilot study. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 2954-2961.	1.3	31
172	Two immunocytochemical protocols for immunofluorescent detection of c-Fos positive neurons in the rat brain. Brain Research Protocols, 2004, 13, 45-52.	1.7	30
173	Appropriateness of Colonoscopy in the Era of Colorectal Cancer Screening: A Prospective, Multicenter Study in a Private-Practice Setting (Berlin Colonoscopy Project 1, BECOP 1). Diseases of the Colon and Rectum, 2007, 50, 1628-1638.	0.7	30
174	Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients. Endocrine-Related Cancer, 2013, 20, 305-319.	1.6	29
175	Determinants of Quality of Life in Patients With Intestinal Failure Receiving Longâ€Term Parenteral Nutrition Using the SFâ€36 Questionnaire: A German Singleâ€Center Prospective Observational Study. Journal of Parenteral and Enteral Nutrition, 2020, 44, 291-300.	1.3	29
176	Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: The Second Event and Some Final Considerations. Neuroendocrinology, 2008, 87, 5-7.	1.2	28
177	CapsoCam SV-1 Versus PillCam SB 3 in the Detection of Obscure Gastrointestinal Bleeding. Journal of Clinical Gastroenterology, 2019, 53, e101-e106.	1.1	28
178	Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1486-1494.	1.8	27
179	Occurrence of a novel DNA virus (TTV) infection in patients with liver diseases and its frequency in blood donors. , 1999, 59, 117-121.		26
180	Characterization of voltage operated R-type Ca2+ channels in modulating somatostatin receptor subtype 2- and 3-dependent inhibition of insulin secretion from INS-1 cells. Cellular Signalling, 2008, 20, 2286-2295.	1.7	26

#	Article	IF	Citations
181	Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines. Frontiers in Endocrinology, 2018, 9, 146.	1.5	26
182	Successful Therapy of Refractory Pyoderma Gangrenosum and Periorbital Phlegmona With Tacrolimus (FK506) in Ulcerative Colitis. Inflammatory Bowel Diseases, 2004, 10, 421-424.	0.9	25
183	8. Multidisciplinary Approach for the Treatment of Neuroendocrine Tumors. Tumori, 2010, 96, 833-846.	0.6	24
184	Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. Gut, 2021, 70, 1904-1913.	6.1	24
185	Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors. European Journal of Radiology, 2013, 82, e550-e555.	1.2	23
186	Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. International Journal of Cancer, 2003, 107, 844-853.	2.3	22
187	Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options. Neuroendocrinology, 2020, 110, 517-524.	1.2	22
188	DISTINCT ENZYME PROFILES IN PATIENTS WITH CRYPTOGENIC CIRRHOSIS REFLECT HETEROGENEOUS CAUSES WITH DIFFERENT OUTCOMES AFTER LIVER TRANSPLANTATION (OLT): A LONG-TERM DOCUMENTATION BEFORE AND AFTER OLT. Transplantation, 2002, 74, 792-798.	0.5	21
189	Somatostatin Receptor Targeting for Tumor Imaging and Therapy. Annals of the New York Academy of Sciences, 2004, 1014, 258-264.	1.8	21
190	Systematic High-Content Proteomic Analysis Reveals Substantial Immunologic Changes in Colorectal Cancer. Cancer Research, 2008, 68, 880-888.	0.4	21
191	Bombesin, but not amylin, blocks the orexigenic effect of peripheral ghrelin. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R903-R913.	0.9	20
192	ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors. Neuroendocrinology, 2009, 90, 159-161.	1.2	20
193	Syndromic versus non-syndromic sporadic gastrin-producing neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 277-287.	1.4	20
194	Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms. Neuroendocrinology, 2019, 108, 7-17.	1.2	19
195	Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals. International Journal of Cancer, 2020, 146, 1316-1323.	2.3	19
196	Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3. American Journal of Surgery, 2020, 220, 284-289.	0.9	19
197	Hepatitis-C Patients Have Reduced Growth Hormone (GH) Secretion Which Improves During Long-Term Therapy With Pegylated Interferon-Î±. American Journal of Gastroenterology, 2007, 102, 2724-2731.	0.2	18
198	Cardiac surgery for carcinoid heart disease in 12 cases. General Thoracic and Cardiovascular Surgery, 2011, 59, 780-785.	0.4	18

#	Article	IF	Citations
199	Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3). Cancers, 2021, 13, 1936.	1.7	18
200	Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery). European Journal of Cancer, 2008, 44, 2162-2168.	1.3	17
201	Prospective, randomized comparison of mechanical and electronic radial endoscopic ultrasound systems: Assessment of performance parameters and image quality. Scandinavian Journal of Gastroenterology, 2009, 44, 93-99.	0.6	17
202	Peripherally injected CCK-8S activates CART positive neurons of the paraventricular nucleus in rats. Peptides, 2010, 31, 1118-1123.	1.2	17
203	Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. Neuroendocrinology, 2021, 111, 217-236.	1.2	17
204	Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review. Cancers, 2020, 12, 733.	1.7	17
205	Management of Severe Refractory Adult Autoimmune Enteropathy with Infliximab and Tacrolimus. Digestion, 2005, 71, 141-144.	1.2	16
206	Prospective pilot evaluation of a new needle prototype for endoscopic ultrasonography-guided fine-needle aspiration: comparison of cytology and histology yield. European Journal of Gastroenterology and Hepatology, 2008, 20, 342-348.	0.8	16
207	Electrical Activity and Calcium Channels in Neuroendocrine Cells. Annals of the New York Academy of Sciences, 1994, 733, 335-339.	1.8	14
208	Adding interferon-Î± to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours. Cancer Treatment Reviews, 2003, 29, 565-569.	3.4	14
209	Insulinostatic activity of cerebellin â€" Evidence from in vivo and in vitro studies in rats. Regulatory Peptides, 2009, 157, 19-24.	1.9	14
210	All-trans-Retinoic Acid-mediated Growth Inhibition Involves Inhibition of Human Kinesin-related Protein HsEg5. Journal of Biological Chemistry, 1999, 274, 18925-18931.	1.6	13
211	Neuroendocrine-Specific and Gastrin-Dependent Expression of a Chromogranin A-Luciferase Fusion Gene in Transgenic Mice. Gastroenterology, 2001, 121, 43-55.	0.6	13
212	Insulin-Like Growth Factor-1 Increases Intracellular Calcium Concentration in Human Primary Neuroendocrine Pancreatic Tumor Cells and a Pancreatic Neuroendocrine Tumor Cell Line (BON-1) via R-Type Ca²⁺ Channels and Regulates Chromogranin A Secretion in BON-1 Cells. Neuroendocrinology, 2005, 82, 87-102.	1.2	13
213	Quantification in ⁶⁸Ga-DOTA(0)-Phe(1)-Tyr(3)-Octreotide Positron Emission Tomography/Computed Tomography: Can We Be Impartial about Partial Volume Effects?. Neuroendocrinology, 2013, 97, 369-374.	1.2	13
214	Extremely Long Survival under Combined Immunotherapy in a Metastatic Functional Neuroendocrine Neoplasia Patient. Neuroendocrinology, 2018, 106, 381-388.	1.2	13
215	Neuroendocrine neoplasia goes molecular â€" time for a change. Nature Reviews Clinical Oncology, 2019, 16, 149-150.	12.5	13
216	New Molecular Aspects for the Diagnosis and Treatment of Neuroendocrine Gastroenteropancreatic Tumors. Annals of the New York Academy of Sciences, 1994, 733, 515-515.	1.8	12

#	Article	IF	Citations
217	Relevance of endotoxin receptorCD14andTLR4gene variants in chronic liver disease. Scandinavian Journal of Gastroenterology, 2008, 43, 584-592.	0.6	12
218	Sulfated cholecystokinin-8 activates phospho-mTOR immunoreactive neurons of the paraventricular nucleus in rats. Peptides, 2011, 32, 65-70.	1.2	12
219	Glucagon regulates orexin A secretion in humans and rodents. Diabetologia, 2014, 57, 2108-2116.	2.9	12
220	Staged Catheter-Based Valve Treatment of Severe Carcinoid Heart Disease. Neuroendocrinology, 2016, 103, 259-262.	1.2	12
221	Efficacy and Toxicity of 5-Fluorouracilâ€“Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms. Pancreas, 2020, 49, 912-917.	0.5	12
222	ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. Journal of Neuroendocrinology, 2022, 34, e13040.	1.2	12
223	Tumor suppressor p16^{INK4a} controls oncogenic Kâ€Ras function in human pancreatic cancer cells. Cancer Science, 2012, 103, 169-175.	1.7	11
224	Fra-1: a novel target for retinoid action. FEBS Letters, 1999, 448, 45-48.	1.3	10
225	Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection. Journal of Hepatology, 2008, 49, 339-345.	1.8	10
226	From Basic to Clinical Research in Gastroenteropancreatic Neuroendocrine Tumor Disease â€“ The Clinician-Scientist Perspective. Neuroendocrinology, 2004, 80, 94-98.	1.2	9
227	Ca2+Channel Properties in Neuroendocrine Tumor Cell Cultures Investigated by Whole-Cell Patch-Clamp Technique. Annals of the New York Academy of Sciences, 2004, 1014, 137-139.	1.8	9
228	An Orthotopic Model of Pancreatic Somatostatin Receptor (SSTR)-Positive Tumors Allows Bimodal Imaging Studies Using 3T MRI and Animal PET-Based Molecular Imaging of SSTR Expression. Neuroendocrinology, 2008, 87, 233-242.	1.2	9
229	Identification of novel Cyclooxygenase-2-dependent genes in Helicobacter pylori infection in vivo. Molecular Cancer, 2009, 8, 22.	7.9	9
230	Interactions of Gastrointestinal Peptides: Ghrelin and Its Anorexigenic Antagonists. International Journal of Peptides, 2010, 2010, 1-11.	0.7	9
231	Management of follow-up of neuroendocrine neoplasias. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 129-140.	2.2	9
232	Malnutrition predicts long-term survival in hospitalized patients with gastroenterological and hepatological diseases. Clinical Nutrition ESPEN, 2019, 30, 26-34.	0.5	9
233	Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRIâ€”A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making. Cancers, 2021, 13, 2726.	1.7	9
234	Failure of CD4 T-Cells to Respond to Liver-Derived Antigen and to Provide Help to CD8 T-Cells. PLoS ONE, 2011, 6, e21847.	1.1	9

#	Article	IF	Citations
235	Sodium Butyrate Increases Expression of the Coxsackie and Adenovirus Receptor in Colon Cancer Cells. Cancer Investigation, 2010, 28, 268-274.	0.6	8
236	The CCKB antagonist CI988 reduces food intake in fasted rats via a dopamine mediated pathway. Peptides, 2013, 39, 111-118.	1.2	8
237	Near-Infrared Confocal Laser Endomicroscopy Detects Colorectal Cancer via an Integrin Î±vÎ²3 Optical Probe. Molecular Imaging and Biology, 2015, 17, 450-460.	1.3	8
238	Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumorsâ€"Results from an Exploratory Study. Journal of Clinical Medicine, 2020, 9, 2881.	1.0	8
239	Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Medical Science Monitor, 2018, 24, 8125-8140.	0.5	8
240	Cerebral processing of auditory stimuli in patients with irritable bowel syndrome. World Journal of Gastroenterology, 2006, 12, 1723.	1.4	8
241	Antireflux â€˜barriersâ€™: problems with patient recruitment for a new endoscopic antireflux procedure. European Journal of Gastroenterology and Hepatology, 2009, 21, 1110-1118.	0.8	7
242	ENETS Consensus Guidelines for the Management of Patients with Rare Metastases from Digestive Neuroendocrine Tumors: Rationale and Working Framework. Neuroendocrinology, 2010, 91, 324-325.	1.2	7
243	SPECT/CT Imaging, Biodistribution and Radiation Dosimetry of a 177Lu-DOTA-Integrin Î±vÎ²6 Cystine Knot Peptide in a Pancreatic Cancer Xenograft Model. Frontiers in Oncology, 2021, 11, 684713.	1.3	7
244	PD-L1 â€“ inhibitors in neuroendocrine neoplasia. Medicine (United States), 2021, 100, e23835.	0.4	7
245	Advanced liver function assessment in patients with intestinal failure on long-term parenteral nutrition. Clinical Nutrition, 2020, 39, 540-547.	2.3	6
246	Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies. Journal of Clinical Medicine, 2020, 9, 1647.	1.0	6
247	Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab. Oncotarget, 2019, 10, 3302-3311.	0.8	6
248	Interferon-Î± inhibits chromogranin A promoter activity in neuroendocrine pancreatic cancer cells. FEBS Letters, 1999, 458, 378-382.	1.3	4
249	A novel function for the tumor suppressor p16INK4a: Induction of anoikis via upregulation of the A5B1 fibronectin receptor. Gastroenterology, 2000, 118, A664.	0.6	4
250	Increased Activity of the Immunoregulatory Enzyme Indoleamine-2,3-Dioxygenase with Consecutive Tryptophan Depletion Predicts Death in Patients with Neuroendocrine Neoplasia. Neuroendocrinology, 2017, 104, 135-144.	1.2	4
251	Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets.. Journal of Clinical Oncology, 2013, 31, e15071-e15071.	0.8	4
252	Evaluation of Angiotensinogen c.1-44G>A and p.M268T Variants as Risk Factors for Fibrosis Progression in Chronic Hepatitis C and Liver Diseases of Various Etiologies. Genetic Testing and Molecular Biomarkers, 2009, 13, 407-414.	0.3	2

#	Article	IF	Citations
253	Percutaneous transhepatic cholangiodrainage under real-time MRI guidance: Initial experience in an animal model. Digestive and Liver Disease, 2011, 43, 642-646.	0.4	2
254	Successful treatment of high-grade pancreatic neuroendocrine neoplasms with everolimus. Acta OncolÃ³gica, 2018, 57, 686-688.	0.8	2
255	Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers, 2021, 13, 4463.	1.7	2
256	Secretin Receptor as a Target in Gastrointestinal Cancer: Expression Analysis and Ligand Development. Biomedicines, 2022, 10, 536.	1.4	2
257	Prospective, randomized multicenter trial on the antiproliferative effect of lanreotide, interferon-a and the combination for therapy of metastatic neuroendocrine gep-tumors. Gastroenterology, 2000, 118, A177.	0.6	1
258	M1677 Galectin-2 and Galectin-4 Modulate Intestinal Epithelial Cell Function and Intestinal Wound Healing. Gastroenterology, 2008, 134, A-395.	0.6	1
259	ERCP in the Sitting Positionâ€"An Alternative Technique With Potential Benefits (With Video). Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2010, 20, 247-249.	0.4	1
260	MRI-guided percutaneous transhepatic cholangiodrainage: feasibility study in a porcine model. Scandinavian Journal of Gastroenterology, 2014, 49, 722-726.	0.6	1
261	AGTR1 Is Overexpressed in Neuroendocrine Neoplasms, Regulates Secretion and May Potentially Serve as a Target for Molecular Imaging and Therapy. Cancers, 2020, 12, 3138.	1.7	1
262	Synaptophysin: A Major Cell Type-Specific Vesicle Protein of Neuroendocrine Cells. , 1988, , 351-356.		1
263	Megacolon in adulthood after surgical treatment of Hirschsprungâ€™s disease in early childhood. World Journal of Gastroenterology, 2005, 11, 5742.	1.4	1
264	Response:. Gastrointestinal Endoscopy, 2001, 54, 805.	0.5	0
265	Foreword. Neuroendocrinology, 2013, 97, 5-6.	1.2	0
266	Reply to â€˜Time for a change and to adopt a novel molecular genomic approach in NETsâ€™. Nature Reviews Clinical Oncology, 2019, 16, 270-270.	12.5	0
267	Malignome endokriner Organe. , 2007, , 885-936.		0
268	Karzinoid, neuroendokrine Tumoren und Karzinoid-Syndrom. , 2010, , 493-502.		0
269	Streptozocin-based chemotherapy in patients with advanced pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2014, 32, 295-295.	0.8	0
270	Malignome endokriner Organe. , 2017, , 909-960.		0

#	Article	IF	Citations
271	Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality.. Journal of Clinical Oncology, 2019, 37, e13524-e13524.	0.8	0
272	Neuroendokrine Tumoren des Pankreas und des Gastrointestinaltrakts. , 2007, , 984-989.		0